E-LIB Suche - Ergebnisse für: Cartechini, G.

1

Mitigating Oral Mucositis in Proton Therapy with Advanced D..:

Cartechini, G. ; Liu, S. ; Washington, C...
International Journal of Radiation Oncology*Biology*Physics. 118 (2024) 5 - p. e55 , 2024

Link: https://doi.org/10.1016/..

2

PO-1611: Clinical implementation of liver cancer treatments..:

Fracchiolla, F. ; Dionisi, F. ; Righetto, R....
Radiotherapy and Oncology. 152 (2020) - p. S877 , 2020

Link: https://doi.org/10.1016/..

3

PO-1425: Secondary cancer risk in breast cancer patients tr..:

Tommasino, F. ; Cartechini, G. ; Fracchiolla, F....
Radiotherapy and Oncology. 152 (2020) - p. S757 , 2020

Link: https://doi.org/10.1016/..

4

Circulating Catecholamine and Glucagon Responses to Insulin..:

BOLLI, GEREMIA ; FEO, PIERPAOLO DE ; MASSI-BENEDETTI, MASSIMO...
The Journal of Clinical Endocrinology & Metabolism. 54 (1982) 2 - p. 447-449 , 1982

Link: https://doi.org/10.1210/..

5

Lack of glucagon response in glucose counter-regulation in ..:

Bolli, G. ; Calabrese, G. ; De Feo, P....
Diabetologia. 22 (1982) 2 - p. 100-105 , 1982

Link: https://doi.org/10.1007/..

6

Modification of glycosylated haemoglobin concentration duri..:

Bolli, G. ; Cartechini, Maria G. ; Compagnucci, P....
Diabetologia. 18 (1980) 2 - p. 125-130 , 1980

Link: https://doi.org/10.1007/..

7

Urinary excretion and plasma levels of norepinephrine and e..:

Bolli, Geremia ; Compagnucci, Pietro ; Cartechini, Maria G....
Acta Diabetologica Latina. 16 (1979) 2 - p. 157-167 , 1979

Link: https://doi.org/10.1007/..

8

Microdosimetric measurements as a tool to assess potential ..:

Missiaggia M ; Cartechini G ; Scifoni E...
info:eu-repo/semantics/altIdentifier/pmid/32554886. , 2020

Link: http://hdl.handle.net/11..

9

Association of kidney disease measures with risk of renal f..:

Mirijello, Antonio ; Viazzi, Francesca ; Fioretto, Paola...
info:eu-repo/semantics/altIdentifier/pmid/30514308. , 2018

Link: http://hdl.handle.net/23..

10

Association of kidney disease measures with risk of renal f..:

Mirijello A ; Viazzi F ; Fioretto P...
info:eu-repo/semantics/altIdentifier/pmid/30514308. , 2018

Link: http://hdl.handle.net/10..

11

Association of kidney disease measures with risk of renal f..:

Mirijello A ; Viazzi F ; Fioretto P...
info:eu-repo/semantics/altIdentifier/pmid/30514308. , 2018

Link: http://hdl.handle.net/24..

12

Integrating microdosimetric in vitro RBE models for particl..:

Cartechini, Giorgio ; Missiaggia, Marta ; Scifoni, Emanuele..
Physics in Medicine & Biology. 69 (2024) 4 - p. 045005 , 2024

Link: https://doi.org/10.1088/..

13

Comparative effectiveness and cost-effectiveness of nataliz..:

Spelman, T. ; Herring, W. L. ; Acosta, C....
Journal of Medical Economics. 27 (2023) 1 - p. 109-125 , 2023

Link: https://doi.org/10.1080/..

14

Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Preg..:

Yeh, Wei Zhen ; Widyastuti, Putu Ayu ; Van der Walt, Anneke...
Neurology. 96 (2021) 24 - p. , 2021

Link: https://doi.org/10.1212/..

15

Risk of multiple sclerosis relapses when switching from fin..:

Ferraro, D. ; Iaffaldano, P. ; Guerra, T....
Journal of Neurology. 269 (2021) 3 - p. 1463-1469 , 2021

Link: https://doi.org/10.1007/..